| pubmed-article:3456079 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0080103 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3456079 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:3456079 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:3456079 | pubmed:dateCreated | 1986-3-10 | lld:pubmed |
| pubmed-article:3456079 | pubmed:abstractText | High-dose methotrexate (500 to 33,600 mg per square meter of body-surface area) with leucovorin rescue is a common component of therapy for acute lymphocytic leukemia. To increase understanding of the relation between the serum concentration and the effect of methotrexate, we conducted a randomized, prospective study of 108 children with "standard-risk" acute lymphocytic leukemia who were treated with 15 doses of methotrexate (1000 mg per square meter) that were infused over 24 hours. The median length of follow-up was 3.5 years from diagnosis for patients still in remission. Variability between patients in methotrexate clearance produced steady-state serum concentrations that ranged from 9.3 to 25.4 microM. Patients with median methotrexate concentrations of less than 16 microM (n = 59) had a lower probability of remaining in remission (P less than 0.05) than patients with concentrations of 16 microM or more (n = 49). Multivariate analyses indicated that patients with methotrexate concentrations of less than 16 microM were 3 times more likely to have any kind of relapse during therapy (P = 0.01) and 7 times more likely to have a hematologic relapse during therapy (P = 0.001). Stepwise Cox's regression identified leukemic-cell DNA content, methotrexate concentration, and hemoglobin as significant prognostic variables for hematologic relapse (P = 0.0005). We conclude that there is a concentration-effect relation for high-dose methotrexate in acute lymphocytic leukemia and that 1000 mg per square meter infused over a period of 24 hours may not be optimal for patients with relatively fast drug clearance. | lld:pubmed |
| pubmed-article:3456079 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3456079 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3456079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3456079 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3456079 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:3456079 | pubmed:issn | 0028-4793 | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:EvansW EWE | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:GeorgeS LSL | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:CromW RWR | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:DodgeRR | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:BowmanW PWP | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:LookA TAT | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:PuiC HCH | lld:pubmed |
| pubmed-article:3456079 | pubmed:author | pubmed-author:AbromowitchMM | lld:pubmed |
| pubmed-article:3456079 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3456079 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:3456079 | pubmed:volume | 314 | lld:pubmed |
| pubmed-article:3456079 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3456079 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3456079 | pubmed:pagination | 471-7 | lld:pubmed |
| pubmed-article:3456079 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:meshHeading | pubmed-meshheading:3456079-... | lld:pubmed |
| pubmed-article:3456079 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3456079 | pubmed:articleTitle | Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. | lld:pubmed |
| pubmed-article:3456079 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3456079 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3456079 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3456079 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:3456079 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3456079 | lld:pubmed |
